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ABSTRACT

This study compared the relative effectiveness and safety of non-vitamin K antagonists oral
anticoagulants (NOACs) versus warfarin in elderly Medicare beneficiaries with NVAF and
diabetes mellitus (DM).
A retrospective cohort study using 2014 - 2016 5% national Medicare data was undertaken. NVAF
patients with DM aged ≥65 years having at least one prescription for NOACs (dabigatran,
rivaroxaban, apixaban, and edoxaban) or warfarin between July, 2014 and December, 2015 were
selected from the database. Date of first NOAC or warfarin prescription was defined as the index
date. Patients initiating NOACs were 1:1 matched to warfarin patients on propensity score and
index date. Stratified Cox proportional hazards models were used to estimate the clinical outcomes
among patients initiating NOAC therapy versus warfarin therapy in the matched cohort.
The matched sample consisted of 4578 patients (2291 in each group). NOACs were found
to significantly reduce the risk of stroke/SE compared to warfarin (Hazard Ratio (HR): 0.373, 95%
confidence interval (CI): 0.247 - 0.564, p<0.001); but, no significant difference was seen between
NOACs and warfarin in terms of reducing the risk of MI (HR: 0.864, CI: 0.594 – 1.257, p=0.446).
NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008)
and OB (HR: 0.608, CI: 0.424 – 0.870, p=0.007); but no difference was seen in the risk of MGB
(HR: 0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. NOACs were also found
to reduce the risk of all-cause mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007). The composite
of effectiveness and safety outcomes, and all-cause mortality was statistically significant proving
ii

superior overall effectiveness and safety of NOAC therapy to warfarin therapy in terms of risk
reduction (HR:0.685, CI:0.587 – 0.801, p<0.001).
Oral anticoagulation therapy with NOACs was found to be more effective than warfarin
therapy. Results of this study may assist in clinical decision-making about anticoagulation
therapies used in elderly NVAF patients with DM.
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CHAPTER I: BACKGROUND
INTRODUCTION
Atrial fibrillation (AF) is the most common heart rhythm disorder in the United States 1. The annual
prevalence of AF in the US population was estimated at 5.2 million in 2010 and projected to
increase to 12.1 million by 2030, corresponding to an annual growth rate of 4.3 percent 2.
Advancing age is the most prominent risk factor for AF with a 1-in-4 lifetime risk after age 40
years 3,4. The Framingham study reported a five-fold increase in the risk of stroke with advancing
age in AF patients 5, while the Scottish Renfrew/Paisley study with a 20-year follow-up found a
three-fold increase in the risk of stroke among AF patients 6. Diabetes is another independent risk
factor of AF with a prevalence of ranging from 24 – 30 percent among AF patients

7,8

. The

relationship between diabetes mellitus and AF is mutual and reciprocal. Incidence of AF in patients
with diabetes has been reported around 14.9% 9. An observational study assessing the impact of
diabetes mellitus (DM) on AF reported that over a mean follow-up of 7.2 ± 2.8 years, diabetic
patients without AF at baseline had an age- and sex-adjusted incidence rate of AF 9.1 per 1,000
person-years (95% CI: 8.6–9.7) compared with a rate of 6.6 (95% CI: 6.2–7.1) among nondiabetic
patients 10. Among diabetes patients, AF was independently associated with a 61 percent greater
risk for vascular death and all-cause mortality and higher risks for cardiovascular death and heart
failure when compared with patients without AF 11.
Since 1950s, vitamin K antagonists (VKA) such as warfarin and low molecular weight
heparins (LMWH) were used for anticoagulation treatment in AF patients. A meta-analysis of
6

thromboembolic and bleeding outcomes by Hart et al. comparing warfarin to antiplatelet drugs in
AF patients found warfarin to reduce the risk of stroke by 60 percent

12

. Bleeding is the most

common side effect of warfarin and occurs in up to 41 percent of patients treated with warfarin.
Additionally, its use can be cumbersome because of its food and drug interactions, dose
adjustment, and need for constant monitoring through laboratory testing

12,13

. Literature reports

VKA therapy discontinuation rates of nearly 30-60 percent among patients with AF, and patients
who discontinued therapy had significantly poor anticoagulation control in terms of poor
International Normalized Ratio (INR), lesser Time in Therapeutic Range (TTR), and resultant
underanticoagulation

14–16

. Beginning 2010, a new class of oral anticoagulants, non-vitamin K

antagonists oral anticoagulants (NOACs) were introduced in the US market. Between 2010 and
2015, the US Food and Drug Administration (FDA) approved four NOACs – dabigatran, apixaban,
rivaroxaban and edoxaban – indicated for thromboprophylaxis in patients with non-valvular AF
(NVAF). Of these, dabigatran is a direct thrombin inhibitor while others are factor Xa inhibitors.
Direct targeting of factor Xa and thrombin provides a faster onset of action compared to warfarin,
predictable pharmacokinetics and pharmacodynamics with a lesser potential for food and drug
interactions allows for better fixed dosing schedules without dietary restrictions or routine
coagulation monitoring 13.
Several randomized clinical trials (RCTs) have demonstrated that NOACs have at least
equivalent efficacy and safety as compared to warfarin in terms of stroke/systemic embolism (SE)
reduction and major hemorrhage rates, in patients with NVAF

17–20

. Results of phase III RCTs

conducted in a sub-group of NVAF patients with diabetes report that NOACs have superior
efficacy compared to warfarin. However, the safety profile of NOACs present a complex scenario.
Bleeding events of NOACs were found to vary by a specific NOAC and dosage. While high dose

7

edoxaban (60 mg)

20

, as compared to low dose edoxaban (30 mg) and warfarin, reduced major

bleeding in both NVAF patients with and without diabetes, apixaban

21

reduced major bleeding

only among nondiabetic patients with NVAF, with no significant interaction by diabetes status.
Interestingly, in patients with diabetes and NVAF, dabigatran and rivaroxaban were not
significantly different from warfarin in reducing the risk of major bleeding, and there was no
significant interaction by diabetes status 22,23.
Proven efficacy and safety in RCTs, and the pharmacological characteristics of NOACs
contribute to their practical advantages over traditional VKA therapy in reducing thromboembolic
risk 13. With widespread adoption of NOACs in the routine practice, several observational studies
have been conducted to assess real world effectiveness and safety of these drugs 24–31. These studies
report a comparable or superior performance of NOACs to warfarin in stroke/SE reduction in
patients with AF, but a variation in bleeding outcomes. Apixaban was found to have the lowest
bleeding risk as compared to warfarin followed by dabigatran and rivaroxaban. Rivaroxaban was
associated with higher bleeding risk as compared to warfarin, especially in elderly population32–
34

.
While research has been conducted in the geriatric population with AF and diabetic patients

with NVAF, no real world evidence is available in comparing the effectiveness and safety of
NOAC therapy with warfarin in elderly NVAF patients with comorbid diabetes 35. NVAF patients
with DM are at an increased risk of thromboembolic and bleeding events due to the synergistic
effect of DM and aging. Given the complex clinical interactions between AF and diabetes, care
for elderly NVAF patients with DM can be complicated. Evidence obtained through this
observational study may assist in clinical decision-making pertaining to the choice of oral
anticoagulation therapy in patients with simultaneous presence of both AF and DM 35,36. This study

8

assessed the comparative effectiveness and safety of NOAC therapy versus traditional warfarin
therapy in elderly NVAF patients with concomitant diabetes mellitus using 5% national Medicare
data.

9

LITERATURE REVIEW
Atrial Fibrillation – Pathophysiology and Etiology
According to the American Heart Association, atrial fibrillation (AF) is defined as “a quivering or
irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heartrelated complications.”1 It is a type of supraventricular tachycardia which starts as brief periods
of abnormal beating which become longer and possibly constant over time. The arrhythmia is
characterized by chaotic, electrical conduction in the atria. In AF, the cardiac neuronal signals
begin in another part of atria or near the pulmonary veins instead of sinoatrial (SA) node. Spreading
of faulty neuronal signals in a rapid, disorganized way can cause the atria to fibrillate. These signals
then flood the atrioventricular (AV) node causing the ventricles to beat faster.
AF may be classified based on etiology, depending on whether it occurs without
identifiable etiology in patients with a structurally normal heart (lone AF), or whether it
complicates hypertensive, valvar, ischemic or other structural heart disease. Lone AF accounts for
about 15% of the total AF cases.37 AF maybe termed as non-valvular AF (NVAF) in absence of
rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair. If AF occurs in the
setting of a primary condition that maybe the cause of the AF such as acute myocardial infarction,
cardiac surgery, pericarditis, myocarditis, hyperthyroidism, pulmonary embolism, pneumonia, or
other acute pulmonary disease, it may be classified as secondary AF.37
Based on the temporal pattern of the arrhythmia, a system of clinical classification has been
recommended. The American College of Cardiology (ACC), American Heart Association (AHA),
and the European Society of Cardiology (ESC) recommend in their guidelines the following
classification system based on simplicity and clinical relevance.38 Patients presenting to medical
attention may have a first detected episode of AF or, if previous episodes have been documented,
10

recurrent arrhythmia. Episodes themselves may be paroxysmal, if they terminate spontaneously,
usually within seven days, or persistent if the arrhythmia continues requiring electrical or
pharmacological cardioversion for termination. AF that cannot be successfully terminated by
cardioversion, and longstanding (>1 year) AF, where cardioversion is not indicated or has not been
attempted, is termed permanent.
Epidemiology of AF
AF is the most common clinically significant cardiac arrhythmia in the US.5 Global prevalence of
AF in 2010 was estimated to be around 33.5 million (20.9 million males and 12.6 million females).
AF was found to be more prevalent among men than women. Between 1990-2010, the global
incidence rate increased from 60.7 per 1000 person-years in males to 77.5 per 1000 person-years,
and from 43.8 to 59.5 per 1000 person-years in females.39 The annual prevalence of AF in the US
population was estimated at 5.2 million in 2010 and projected to increase to 12.1 million by 2030,
corresponding to a growth rate of 4.3%.2 The prevalence of AF was found to increase with age,
and it is estimated that over 80% of US adults with AF are 65 years or older and approximately
37% are 80 years or older.40 Aging is associated with regional conduction slowing, anatomically
determined conduction delay at the crista, and structural changes that include areas of low voltage
in cardiac musculature. In addition, impairment of sinus node function and an increase in atrial
refractoriness occurs with aging. This electrical and structural remodeling may explain the
increased propensity to AF with aging.41
Apart from the elderly population, approximately 12-30% of AF has been reported to occur
in athletes and younger individuals as “lone AF” (AF with no underlying heart disease).40 These
patients typically have few comorbidities, yet are usually very symptomatic upon presentation.
Researchers from the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study

11

(N=17,974) reported that African Americans and Latinos were less likely diagnosed with AF when
compared with Whites with rates of 3.6%, 2.5%, and 84.7%, respectively. Others have supported
the finding of a lower prevalence of AF in African Americans, Hispanics, and Asians compared to
Whites.40,42–44
Economic and Disability Burden Of AF
High mortality and morbidity associated with AF imposes a significant financial burden. However,
coexistent cardiovascular and non-cardiovascular comorbidities make estimation of direct
healthcare costs attributable to AF difficult. The total costs of AF were estimated to be around 6.65
billion USD (2005 dollars). Nearly 75% of the costs of AF represent the direct and indirect costs
associated with hospitalization. Hospital costs are higher among AF patients not only because of
the initial stay but also because of the frequent need for readmission.45 One study reported that
medical costs for people with AF were $8,705 higher than people without AF.46 Stroke and
hemorrhage associated with non-valvular atrial fibrillation (NVAF) represent a substantial fraction
of the economic burden. A retrospective analysis of Medicare beneficiaries found that the
hemorrhage and stroke-related cost per NVAF patient was $64,956 and $63,781 USD respectively
as compared to $35,474 per NVAF patient without stroke or hemorrhage.47
The pathophysiology of AF predisposes patients with AF at a greater thromboembolic risk. It is
associated with a 3- to 5- fold increase in risk of stroke and causes 15%–20% of ischemic strokes,
which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in
the blood vessel lining.42,6 Strokes caused by complications from AF tend to be more severe than
strokes with other underlying causes.42 AF is a chronic, debilitating disorder which has a
progressive negative impact on patients’ quality of life. Burden associated with AF, measured as
disability adjusted life-years (DALYs), increased by 18.8% in males and 18.9% in females, from
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1990 to 2010. Mortality associated with AF was greater among women, and increased 2-fold and
1.9-fold in males and females respectively from 1990-2010.39 The growing epidemic of AF is
responsible for about 750,000 hospitalizations annually and contributes to an estimated 130,000
deaths each year.48
Risk Factors Of AF
Other than structural heart diseases, other factors involved in initiation or maintenance of AF may
include inflammation, atrial ischemia, autonomic nervous system activity, atrial dilation, and
structural fibrosis associated with aging. Familial AF is well described, although at present this
subtype of AF is rare.43 Over the past decade, population-based studies have suggested that AF is
a heritable disease.49,50
While age and genetics are non-modifiable risk factors for AF, several modifiable risk
factors for AF have been identified in the literature. Many modifiable risk factors associated with
atherosclerotic vascular disease have also been associated with development of AF.51 Increased
left atrial pressure, as seen with hypertension and some valvular diseases, have been hypothesized
to provide a substrate for AF, but the causal link remains unclear. This might explain higher
incidence of AF seen among hypertensive patients.52 Obesity has been found to be associated with
increase pericardial fat volume and increased epicardial fat thickness, which may lead to altered
atrial electrophysiology and sympathovagal imbalance of the atria.53,54 Clinically, epicardial fat
has been associated with AF.55 Obstructive sleep apnea is highly prevalent among AF patients. In
a prospective analysis, approximately 50% of AF patients had OSA, as compared with 32% of
controls.56 Mechanisms by which OSA contributes to AF risk include intermittent nocturnal
hypoxemia/ hypercapnia, surges in sympathetic tone and blood pressure during apneic episodes,
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and increased inflammation. These factors may contribute to left atrial remodeling and chamber
dilation, contributing to development of AF.57,58
Diabetes is an independent risk factor for AF. 59,60 Both AF and type 2 diabetes are chronic
diseases that increase in prevalence and severity with age and are each independently associated
with an increased risk for stroke, heart failure, and death. In 2015, 30.3 million Americans, or 9.4%
of the population, had diabetes. Among older Americans aged 65 years and older, nearly 25.2% or
12.0 million had diabetes.61 The annual prevalence of AF in the US population was estimated at
5.2 million in 2010 and projected to increase to 12.1 million by 2030, corresponding to a growth
rate of 4.3%.2 Significant research has been conducted to understand the pathophysiological
association between diabetes and AF. Diabetes is associated with numerous metabolic defects
including insulin resistance, impaired glucose tolerance, proinflammatory mediators,
abnormalities of hemostasis, fibrinolysis, angiogenesis and extracellular matrix turnover.62–64 All
of these metabolic changes lead to endothelial dysfunction, abnormal activation of the reninangiotensin-aldosterone system (RAAS) and acceleration of atherogenesis, which could be
responsible for AF occurrence. Diabetes could also cause structural, electrical, electromechanical
and autonomic remodeling.65
Literature reports that diabetes is associated with a 35% to 60% relative increase in the risk
for developing AF after adjustment for confounders.66–68 Also, AF patients with diabetes were
found to have higher mortality and higher rates of myocardial infarction as compared to those with
diabetes mellitus alone.69 The Action in Diabetes and Vascular Disease: preterAx and diamicroNMR Controlled Evaluation Trial found that in patients with type 2 diabetes, after adjusting for
confounders, AF was independently associated with a 61% greater risk for death and all-cause
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mortality and higher risks for cardiovascular death and heart failure when compared with patients
without AF.11
Thromboembolic Risk Estimation In AF
Given the diversity of risk factors involved in development or exacerbation of AF and
thromboembolism, several risk scoring systems have been developed to calculate and stratify the
risk of stroke. The risk of stroke is estimated using the CHADS2 score or the CHA2DS2-VASc
score. These scores calculate the risk of stroke by assigning specific weights to major risk factors
of AF which can cause stroke. The 2014 American Heart Association (AHA) /American College
of Cardiology (ACC) /Heart Rhythm Society (HRS) guidelines and the 2016 European Society of
Cardiology (ESC) guidelines on AF recommend using the CHA2DS2-VASc score for
thromboembolic risk estimation.43,70 However, the major clinical trials of non-vitamin K
antagonists oral anticoagulants (NOACs) – the RE-LY trial (dabigatran versus warfarin), the
ARISTOTLE trial (apixaban versus warfarin), the ROCKET-AF trial (rivaroxaban versus
warfarin) and the edoxaban versus warfarin trial – have used CHADS2 score for estimating the
thromboembolic risk.17–20
The CHADS2 score system is based upon a cumulative scoring system focusing on five
major risk factors: congestive heart failure, hypertension, age ≥ 75 years, diabetes, and history of
stroke or transient ischemic attack.71 Each factor is scored 1, except the cerebral events scored 2
points, reflecting their increased weight. The original validation of the score classified CHADS2
score of 1-2 as moderate, and CHADS2 > 2 as high risk.71 The CHA2DS2-VASc score is also based
upon a cumulative scoring system focusing on congestive heart failure, hypertension, age >75
years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category
[female] to estimate the risk for stroke in patients with AF.72,73 Both, the 2014 AHA/ACC/HRS
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guidelines and the 2016 ESC guidelines on AF recommend using CHA2DS2-VASc score for
calculation of thromboembolic risk since it is more comprehensive and considers more risk factors
in predicting the risk of stroke.43,70,74
Anticoagulation in AF
Since 1950s, warfarin, a vitamin K antagonist (VKA), has been the mainstay treatment
thromboprophylaxis in NVAF (NVAF) patients.43 It is an oral medication to be administered once
daily. Treatment is monitored using prothrombin time (PT) or international normalized ratio (INR)
to calculate the time for blood clotting. Bleeding is the most common side effect of warfarin and
occurs in up to 41% of patients treated with warfarin, with rates of major bleeding in practice of
about 7 – 8% per year.75,76 An observational study reported that warfarin-related hemorrhage rates
were 11.8% among older adults and were highest during first 30 days of warfarin therapy.14 Other
rare yet severe adverse effects include tissue necrosis, calciphylaxis, and systemic atheroemboli
and cholesterol microemboli.77 Thus, although the treatment with warfarin can reduce the risk of
stroke by 60% to 70%, its use can be cumbersome because of its food and drug interactions,
hemorrhage, dose adjustment and need for constant monitoring through laboratory testing.43,77
Recently, the US Food and Drug Administration approved a new class of non-vitamin K
antagonist oral anticoagulants (NOACs). NOACs are direct thrombin (dabigatran) or factor Xa
(rivaroxaban, apixaban, edoxaban) inhibitors indicated for oral anticoagulation among NVAF
patients. Currently, four NOACs are available in the market – dabigatran, apixaban, rivaroxaban
and edoxaban.
Phase III clinical trials of these NOACs have demonstrated at least equivalent efficacy and
safety as compared to warfarin in terms of stroke/systemic embolism (SE) reduction and major
hemorrhage rates, respectively in patients with NVAF.17–20 For example, in the ARISTOTLE trial
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comparing apixaban to warfarin, apixaban at a dose of 5 mg twice daily was found superior to
warfarin in preventing stroke/SE (1.27% per year vs 1.60% in warfarin group, hazard ratio with
apixaban- 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01
for superiority), caused less bleeding (2.13% per year vs 3.09% per year in the warfarin group,
hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001) and had lower mortality rates (3.52% vs 3.94%,
(hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047).17
Comparison of NOACs and VKAs
The pharmacological characteristics of NOACs contribute to their practical advantages over VKA
therapy in reducing thromboembolic risk.13 Direct targeting of factor Xa and thrombin provides a
faster onset of action, predictable pharmacokinetics and pharmacodynamics with a lesser potential
for food and drug interactions allows for better fixed dosing schedules without dietary restrictions
or routine coagulation monitoring. However, there are disadvantages to NOAC therapy as well.
Unlike VKAs, NOACs are eliminated renally; renal impairment affects the efficacy of NOACs
and increases the associated risk of bleeding.14,75,76 Hence, NOACs are not indicated in patients
with creatinine clearance (CrCl) < 15 mL/min (apixaban, edoxaban and rivaroxaban) and < 30
mL/min (dabigatran).78–81 NOACs have a faster onset of action with a short elimination half-life.
Hemostasis is restored approximately 12–24 h after cessation of NOACs, assuming normal renal
function. If a patient is experiencing non-life-threatening bleeding, discontinuation of the NOACs
and supportive management should suffice. However, in case of life-threatening bleeding, in
addition to discontinuation of the NOAC, administration of a reversal agent should be
considered.82 Currently, only one reversal agent, idarucizumab is available in the market for
reversal of dabigatran-induced anticoagulation.83 Another factor Xa inhibitor reversal agentandexanet alfa has demonstrated efficacy in preclinical studies. Similarly, a synthetic small
17

molecule antidote ciraparantag has shown efficacy in reversal of anticoagulation of all NOACs in
rat models.84 Till these specific reversal agents become available, life-threatening bleeding with
NOACs can be a potential deterrent of use.
Indirect mechanism of action of VKAs which results in slower onset and offset of
anticoagulation effect, inherent prothrombotic effect of VKAs which increases the risk of stroke
in the first 30 days on therapy initiation, narrow therapeutic range necessitating constant
monitoring of international normalized ratio (INR) and food and drug interactions with VKA
therapy are contributing to their under-prescription in patients with high risk of stroke and systemic
embolism.13 In the GARFIELD-AF registry, 38.0% of patients with a CHADS2 score ≥2 did not
receive anticoagulant therapy; 7.2% of patients with AF and CHADS2 ≥2 had refused treatment
for various reasons, including inconvenience of regular blood tests, dietary restrictions, bleeding
risk and an under-appreciation or lack of knowledge regarding the risk of stroke.85 As well as
being unwilling to start VKA therapy, many patients with AF who initiated VKA therapy
discontinue or are non-adherent. For example, of 125,195 patients newly diagnosed with AF in
Canada from 1997 to 2008, 9% did not collect their second prescription of warfarin within the first
half year and 32% discontinued therapy within 1 year, rising to 43% at 2 years and 61% at 5
years.14 Similarly, in a US study, more than one in four new warfarin starters discontinued therapy
within a year.15 In another study, 40% of patients were non-adherent to VKA therapy (>20% of
days with missed doses or >10% of days where extra doses were taken in addition to the prescribed
dose), and this percentage was significantly associated with poor anticoagulation control.16 These
limitations and inconvenience with VKA therapy and the equivalent efficacy of NOACs, faster
onset of action, lack of food and drug interactions, convenient and hassle-free monitoring of
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therapy has made NOACs the first choice of treatment for thromboprophylaxis in patients with
NVAF.43,70
Effectiveness of NOACs in-the-real-world studies
The safety and efficacy of NOACs seen in the randomized clinical trials may not always reflect in
real world practice because of the differences in the patient populations, the intensity of followup, and the variations in care received by the patients. Several systematic reviews and meta
analyses of randomized clinical trials and observational studies have been conducted to compare
the efficacy and safety of NOACs versus VKAs in patients with AF.86–90
Lin et al. found NOACs to be associated with lower risk systemic stroke/embolism and
intracranial bleeding as compared to warfarin. Dabigatran 150 mg and rivaroxaban were associated
with greater risk of major bleeding in the elderly population.86 In a systematic review and meta
analyses of 13 RCTs and 27 observational studies (32 for AF), Almutairi et al. found dabigatran
and VKAs were comparable for stroke/SE risk in 1 RCT (HR, 0.77 [95% CI, 0.57–1.03]) and 6
observational studies (HR, 1.03 [95% CI, 0.83–1.27]). Rivaroxaban had a 20% decreased risk of
stroke/SE in 3 RCTs (HR, 0.80 [95% CI, 0.67–0.95]) compared with VKA, but the effect was
nonsignificant in 3 observational studies (HR, 0.78 [95% CI, 0.59–1.04]). Apixaban decreased
stroke/SE risk (HR, 0.79 [95% CI, 0.66–0.95]) compared with VKA in 1 RCT, but edoxaban was
comparable to VKA (HR, 0.99 [95% CI, 0.77–1.28]) in 1 RCT (no observational studies available
for apixaban/edoxaban). Dabigatran, apixaban, and edoxaban decreased the risk of hemorrhagic
stroke, mortality, major bleeding, and ICH by 10% to 71% compared with VKAs but not
rivaroxaban. 87 Apart from rivaroxaban, all NOACs had a decreased risk of major bleeding. An
exhaustive review by Raschi et al. found NOACs to be comparable to VKAs in terms of safety,
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efficacy and effectiveness, and indicated a consistent and clinically relevant reduced risk (more
than 50%) of intracranial bleeding.88
With widespread adoption of NOACs in the routine practice, several observational studies
have been conducted worldwide to assess real world safety and effectiveness of these drugs.24–31
Since edoxaban was approved in early 2015, these studies have compared only 3 NOACS apixaban, dabigatran and rivaroxaban to warfarin in assessing the effectiveness and safety in AF
patients.
Many of these real-world observational studies have been conducted using Danish patient
registries. All Danish studies found NOACs to be of comparable effectiveness in reducing
stroke/SE as compared to warfarin. However, the bleeding rates differed between individual
NOAC.24–27,91 The advantages with NOAC treatment were most pronounced with standard dose in
patients below 80 years, and with dose reduction in patients aged 80 and above.26
In the US, real world observational studies to assess effectiveness and safety of NOACs as
compared to warfarin have been conducted using administrative claims data.28–31 In the
observational study of elderly NVAF patients using Medicare data, Amin et al. found apixaban
(HR, 0.40; 95% CI, 0.31-0.53) and rivaroxaban (HR, 0.72; 95% CI, 0.63-0.83) were significantly
associated with lower risk of stroke/SE compared to warfarin. Apixaban (HR, 0.51; 95% CI, 0.440.58) and dabigatran (HR,0.79; 95% CI 0.69-0.91) were significantly associated with lower risk
of major bleeding; rivaroxaban (HR, 1.17; 95% CI 1.10-1.26) was significantly associated with
higher risk of major bleeding compared to warfarin.31 Yao et al. found that for stroke or systemic
embolism, apixaban was associated with lower risk (hazard ratio [HR] 0.67, 95% CI 0.46–0.98,
P=0.04), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98,
95% CI 0.76–1.26, P=0.98; rivaroxaban: HR 0.93, 95% CI 0.72–1.19, P=0.56). For major

20

bleeding, apixaban and dabigatran were associated with lower risk (apixaban: HR, 0.45, 95% CI
0.34–0.59, P<0.001; dabigatran: HR 0.79, 95% CI 0.67–0.94, P<0.01), and rivaroxaban was
associated with a similar risk (HR 1.04, 95% CI 0.90–1.20], P=0.60). All NOACs were associated
with a lower risk of ICH.30 Thus, there were minor consistencies reported in the differential
bleeding rates of NOACs amongst themselves and as compared to warfarin.
Comparison of bleeding rates between NOACs and warfarin
To facilitate a better understanding of NOAC therapy safety, significant amount of research has
been conducted to evaluate major bleedings (gastrointestinal, intracranial and other sites) rates
associated with NOAC therapy.32,33,91–97 Some studies have focused on a specific bleeding rates
such as gastrointestinal bleeding,94,95,98 while other have looked into major bleeding rates as a
whole.32,33,91,96,97,99,100 In a systematic review and meta analyses of 16 RCTs and 31 observational
studies, Roskell et al. reported that the overall median incidence of major bleeding was 2.1 per 100
patient-years (range, 0.9– 3.4 per 100 patient-years) for RCTs and 2.0 per 100 patient-years (range,
0.2 –7.6 per 100 patient-years) for observational studies.93 The risk of bleeding increased with age
and NOAC-related bleeding risk was higher in patients 65 years of age and older.32,95 In almost all
studies, apixaban was found to have the lowest bleeding risk as compared to warfarin followed by
dabigatran and rivaroxaban. Rivaroxaban was associated with higher bleeding risk as compared to
warfarin, especially in elderly population. Adeboyeje et al. found that relative to warfarin,
dabigatran and apixaban were associated with a 33% lower major bleeding risk, while dabigatran
and apixaban were associated with a 48% lower risk of major bleeding compared with
rivaroxaban.100 Xu et al. have ranked NOACs in terms of their gastrointestinal and intracranial
bleeding risk. Apixaban 5 mg had the lowest gastrointestinal bleeding risk, while apixaban 5 mg,
dabigatran 110 mg, and edoxaban 30 mg had lowest risk of intracranial bleeding.34
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Comparison of NOACs versus warfarin in the elderly population
Elderly NVAF patients are likely to be more severe and have more comorbidities than their
younger counterparts.40 An aging heart is characterized by several anatomical changes such as
regional conduction slowing, atrial remodeling, and structural changes that include areas of low
voltage in cardiac musculature. In addition, impairment of sinus node function and an increase in
atrial refractoriness occurs with aging.41 Advancing age is associated with multiple changes in the
pharmacokinetics of drugs and volume of distribution, albumin concentrations, impaired renal
function, and gastric acid secretion. Of note, advancing age may result in declining renal function
and diminished clearance of medications. These patients are also at an increased risk of bleeding
from anticoagulants.101 Patients aged 65 years and older are predisposed to a greater risk of
thromboembolic and bleeding events because of their age and require special considerations while
initiating anticoagulation therapy.
In separate meta-analyses of NOAC therapy in patients aged 75 years and older,
researchers found a similar or superior efficacy of NOACs compared to warfarin in patients with
AF.102,103 A lack of statistical interaction with age in this analysis indicated that the conclusions to
be drawn from the benefits of NOACs are similar for elderly patients. In a separate study, Sharma
et al reported a similar or superior efficacy of NOACs as compared to VKA in stroke/SE reduction
in the elderly. A non-significantly, higher risk of major bleeding than VKA was observed with
dabigatran 150mg (OR, 1.18, 95% CI, 0.97-1.44) but not with the 110mg dose. Significantly higher
gastrointestinal bleeding risks with dabigatran 150mg (1.78, 1.35-2.35) and 110mg (1.40, 1.041.90) and lower intracranial bleeding risks than VKA for dabigatran 150mg (0.43, 0.26-0.72) and
dabigatran 110mg (0.36, 0.22-0.61) were also observed. A significantly lower major bleeding risk
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compared to VKA was observed for apixaban (0.63, 0.51-0.77), edoxaban 60mg (0.81, 0.67-0.98)
and 30mg (0.46, 0.38-0.57) while rivaroxaban showed similar risk.89
Observational studies have been conducted to explore the NOAC therapy outcomes in
elderly population.31,104–106 Most of these studies found NOACs to be comparable or superior to
warfarin in reduction of stroke/systemic embolism rates in elderly NVAF patients. However, the
bleeding rates were different within the NOACs – apixaban had the lowest major bleeding rate
followed by low-dose dabigatran 110 mg and edoxaban 30 mg and 60 mg. Higher bleeding risk
was associated with rivaroxaban and high-dose dabigatran 150 mg.
Comparison of NOACs versus warfarin in the Diabetes sub-group of AF patients
While NOACs are indicated for thromboprophylaxis in patients with NVAF, their efficacy
and safety has been tested in different sub-groups of NVAF patients such as diabetes, hypertension
and chronic kidney disease during the phase III clinical trials.21–23,107–111
In a meta-analysis of 7 prospective cohort studies and 4 case-control studies, Huxley et al. found
that DM increased the risk of AF by 40% compared to normal patients.60 In an observational study
of the HMO diabetes registry, diabetes was found to be an independent risk factor (26% elevated
risk) for AF among women (HR, 1.26 95% CI, 1.08 –1.46), but diabetes was not a statistically
significant factor among men (1.09, 0.96 –1.24).10 In two observational studies, Huang et al. and
Peacock et al. found DM coexisting with NVAF to be associated with an increased risk of 1-year
all-cause mortality, cardiovascular mortality and a greater incidence of major bleeding.112,113
Among different patient subgroups, studies have been conducted to evaluate efficacy and
safety of NOACs in AF patients with coexistent diabetes. A meta-analysis by Ruff et al. of the
four available NOACs showed no significant association between diabetes and the benefit–risk
ratio of NOACs in patients with AF.102 However, contradictory results related to hemorrhagic risk
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have been reported in clinical trials of AF patients with diabetes receiving NOAC therapy. In the
ARISTOTLE study comparing apixaban to warfarin, apixaban was associated with significantly
lower hemorrhagic risk as compared to warfarin.21 The RE-LY study comparing dabigatran to
warfarin showed comparable bleeding risk but a greater risk reduction of thromboembolic events.23
A significantly reduced rate of intracranial hemorrhage was reported in diabetic patients receiving
dabigatran 110 mg twice daily compared to warfarin, but a non-significant reduction in diabetic
patients receiving dabigatran 150 mg twice daily. In the ROCKET-AF study comparing
rivaroxaban and warfarin, there was no significant association between diabetes and the risk of
hemorrhagic complications.22
In another meta-analysis of phase III randomized trials of NOACs versus warfarin in
diabetic NVAF patients, Patti et al. did not find any interaction between diabetic status and the
benefits of NOACs was found for the occurrence of ischemic stroke, major bleeding, or intracranial
bleeding. However, a significant decrease in vascular deaths (1.02% vs. 0.27%) in diabetic NVAF
patients as compared to non-diabetics (4.97% vs. 5.99% with warfarin) was reported.114
Significance of The Study
AF and diabetes, especially type 2 diabetes, have emerged as global epidemics with significant
effects on morbidity and mortality. The prevalence and incidence of AF increases with age.8
Approximately 5% of the population over the age of 65 years and 10% over the age of 79 years
are affected by AF.115 Nearly 24% of the total population with AF has comorbid diabetes.116 Based
on the meta-analysis of 11 observational studies of 1.6 million patients, diabetes was associated
with a 40% increased risk for AF.42 Given the complex clinical interactions between AF and type
2 diabetes and their associated comorbidities, care for these patients can be complicated, and
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whether the simultaneous presence of both AF and type 2 diabetes deserves special consideration
with regard to clinical decision making remains unclear.35
Randomized clinical trials of NOACs have evaluated the efficacy and safety in different
subgroups of patients such as hypertension, diabetes, heart failure and chronic kidney disease, but
the idealized conditions of the clinical trials are not always replicated in real-world.98-105 Several
observational studies have explored the safety and effectiveness of NOACs in the general patient
population with AF; however, there is a paucity of real-world studies exploring the comparative
safety and effectiveness of NOACs versus warfarin in different subgroups of NVAF patients. No
observational study has been conducted to evaluate the safety and efficacy of NOAC therapy in
elderly NVAF patients with coexistent diabetes. Diabetes and AF are both chronic, severe and
infrequently reversible diseases with significant economic and disability burden. With NOACs
becoming the first line of anticoagulation therapy for stroke prevention, it is important and
necessary to evaluate NOAC therapy outcomes as compared to the traditional warfarin therapy in
elderly NVAF patients with diabetes. This study seeks to provide information to assist in clinical
decision-making about the comparative effectiveness and safety of NOAC therapy versus warfarin
in elderly NVAF patients with coexistent diabetes.
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RESEARCH OBJECTIVE
To compare the effectiveness and safety of non-vitamin K antagonists oral anticoagulants
(NOACs) (dabigatran, rivaroxaban, apixaban, and edoxaban) versus warfarin in elderly Medicare
beneficiaries with non-valvular atrial fibrillation (NVAF) and diabetes mellitus (DM).
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CHAPTER II: METHODOLOGY
DATA SOURCE
A retrospective cohort study was conducted using the 2014-2016 5% national Medicare
administrative claims data from the Centers of Medicare and Medicaid Services (CMS). Medicare
is the federal health insurance program for those aged ≥65 years, people with disabilities, and
people with end-stage renal disease in the United States, with an estimated 38 million fee-forservice beneficiaries 117. Medicare administrative claims include information on hospital inpatient,
outpatient, Medicare carrier, Part D, skilled nursing facility, home health agency, and durable
medical equipment claims. The medical claims are coded using International Classification of
Disease, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision (ICD-10-CM),
Current Procedural Terminology, or Healthcare Common Procedure Coding System codes.
Pharmacy claims include information on drugs dispensed using the National Drug Code coding
system.
Study Population
Elderly patients aged ≥65 years with NVAF and diabetes mellitus having at least one pharmacy
claim for a NOAC (dabigatran, rivaroxaban, apixaban or edoxaban) or warfarin between July 1,
2014 to December 31, 2015 were selected. Index date was defined as the date of first new
prescription claim for a NOAC or warfarin between July 1, 2014 to December 31, 2015. To ensure
the inclusion of only treatment-naïve NOAC and warfarin users, a rolling pre-index
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period of six months was used to confirm that the patients did not have a prior exposure to NOACs
or warfarin. The time period from index date to December 31, 2016 was used for identification of
outcomes; thus, ensuring that each patient had at least 12 months of follow-up period.
Patients were required to have continuous medical (Part A and Part B) and pharmacy (Part
D) enrolment for six months prior to the index date. In Medicare data, beneficiary Part A and Part
B enrollment information is available as single variables showing number of months a beneficiary
was enrolled in Medicare Part A and Part B in a given calendar year. Since, a rolling pre-index
period was used, patients having pre-index period spread across 2014 and 2015 were required to
have at least three months of Part A and Part B continuous enrollment in each calendar year.
Patients were required to have one or more inpatient or outpatient claims carrying a diagnosis code
for NVAF (ICD-9-CM code 427.31 and ICD-10-CM code I48.0, I48.1, I48.2, I48.91)118 and have
at least two outpatient claims or at least one inpatient claim for diabetes (ICD-9-CM code 250.*
and ICD-10-CM code E11.*) within the six-month pre-index period.119
Patients with evidence of valvular heart disease, heart valve replacement or surgery, venous
thromboembolism (VTE), pulmonary embolism, transient AF (pericarditis, hyperthyroidism,
thyrotoxicity), and end-stage renal disease in the pre-index period were excluded from the study.
Patients who underwent hip or knee replacement surgery within six weeks prior to the index date
were excluded. This study also excluded beneficiaries with dual eligibility for Medicare and
Medicaid, and those enrolled in health maintenance organizations (HMOs) during the study period.
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Patients were followed from the index date till the oral anticoagulant (OAC) prescription
discontinuation date, switch to another class of OAC drug other than the index drug class, death,
loss of continuous enrollment or end of the study period (December 31, 2016), whichever occurred
first. Fill dates and days supplied per prescription were used to determine patients’ treatment
episodes, defined as the period from the first fill date to the date when there were no residual days
of supply. Patients were considered as continuing on the treatment as long as they had another
medication fill of the same drug class within 45 days of the end of the last treatment
episode.100,104,120,121
OUTCOME MEASURES
Clinical outcomes associated with NOAC or warfarin therapy were measured from the index date
of NOAC or warfarin therapy till the oral anticoagulant (OAC) prescription discontinuation date,
switch to another class of OAC drug other than the index drug class, death, loss of continuous
enrollment or end of the study period (December 31, 2016), whichever occurred first. Primary
outcomes were classified as effectiveness and safety outcomes. Effectiveness outcomes included
thromboembolic episodes – stroke or systemic embolism (SE), and myocardial infarction (MI).
Safety outcomes included major bleeding episodes - gastrointestinal bleeding (MGB), intracranial
bleeding (ICH), and major bleeding from other sites (OB). Composite effectiveness and composite
safety outcomes comprising of occurrence of any of the effectiveness or safety outcomes,
respectively, were also evaluated. Secondary outcome was a composite of stroke or systemic
embolism (SE), myocardial infarction (MI), gastrointestinal bleeding, intracranial bleeding,
bleeding from other sites, and all-cause mortality. In case a patient encountered multiple clinical
outcomes, the occurrence of the first event was considered for the composite outcome measure.
Outcomes were identified using the Medpar, Outpatient, and Carrier files in the Medicare data.
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All-cause mortality (i.e. patients who died regardless of the reason for death) was identified based
on the date of death information from the Medicare beneficiary summary file.
COVARIATES`
Pre-index period was used for assessment of patient demographics and clinical characteristics
(clinical risk scores, comorbidities, and concomitant medication use). Comorbidities were
evaluated using Charlson comorbidity index and chronic disease count. Chronic disease count was
a simple total of all chronic conditions ever documented for a patient before the index date. This
information was obtained using the Medicare Beneficiary Summary File – Chronic Condition
Summary File. Baseline risk of stroke and major bleeding was assessed using the CHADS 2,
CHA2DS2-VASc, and HAS-BLED scores. CHA2DS2-VASc stroke risk score was based on
CHADS2 and calculated as the summed total of the points determined for each diagnosis
(congestive heart failure, hypertension, age>75 years, diabetes, and prior stroke or transient
ischemic attack, or thromboembolism, vascular disease, aged 65-74 years, and sex). Modified
HAS-BLED bleeding risk score was calculated based on evidence of hypertension, abnormal
kidney or liver function, stroke, bleeding, age>65 years, and drugs/alcohol abuse or dependence.
Labile International Normalized Ratio (INR) is a component of HAS-BLED score. However, since
this information is not available in Medicare administrative claims data, modified HAS-BLED
score with range 0 to 8 was calculated.31 Concurrent medication use was assessed based on paper
by Kocis et al. which describes the extent to which patients with NVAF take chronic medications,
other than anticoagulants, more frequently than once daily.122

30

STATISTICAL ANALYSIS
Descriptive statistics were used to summarize the baseline characteristics of the study cohort.
Frequencies and proportions were reported for categorical variables and means with standard
deviations (SD) were reported for continuous variables.
Patients initiating NOAC or warfarin therapy were expected to differ on baseline
demographic and clinical characteristics and comorbidities. Since the treatment was main variable
of interest, propensity score matching was used to create the final analysis cohort. Propensity
scores were calculated for each patient using multivariable logistic regression. Each patient who
initiated NOAC therapy was matched with a patient who initiated warfarin therapy using a greedy
matching algorithm (i.e. the Mayo gmatch macro)123 based on the calculated propensity scores and
the index date of the therapy. Patients were matched on a 1:1 basis using a caliper width of 0.05
for the propensity score and time period of ±15 days for the index date. Standardized mean
differences were used to assess the balance of the measured covariates and a difference of less than
10% was used to indicate clinically irrelevant difference in the measured variables between the
matched groups.124,125 Since the propensity score matching algorithm picks out the nearest
available match based on the caliper width, patients who initiated NOAC therapy could still differ
on baseline characteristics from patients who initiated warfarin therapy. These group differences
were calculated using standardized differences in the total and the matched sample (Table 1).
The time to each outcome of interest for the propensity-score-matched NOAC and warfarin
treatment cohort was compared using Kaplan–Meier survival curves and tested for differences
using log-rank tests. Incidence rates of stroke or SE, MI, and major bleeding episodes in the
propensity score-matched cohort were calculated as the number of stroke/SE, MI, and major
bleeding events per 100-person years. Stratified Cox proportional hazards regression were used to
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compare outcomes in the propensity score-matched cohort, with STRATA statement in PROC
PHREG procedure to account for the clustering within matched groups. Proportional hazards
assumption was tested and found valid for all outcomes.126 All statistical analyses were performed
using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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Abstract:
Objective: To compare the relative effectiveness and safety of non-vitamin K antagonists oral
anticoagulants (NOACs) versus warfarin in elderly Medicare beneficiaries with NVAF and
diabetes mellitus (DM).
Methods: A retrospective cohort study using 2014 - 2016 5% national Medicare data was
undertaken. NVAF patients with DM aged ≥65 years having at least one prescription for NOACs
(dabigatran, rivaroxaban, apixaban, and edoxaban) or warfarin between July, 2014 and December,
2015 were selected from the database. Date of first NOAC or warfarin prescription was defined as
the index date. Patients initiating NOACs were 1:1 matched to warfarin patients on propensity
score and index date. Stratified Cox proportional hazards models were used to estimate the clinical
outcomes among patients initiating NOAC therapy versus warfarin therapy in the matched cohort.
Results: The matched sample consisted of 4578 patients (2291 in each group). NOACs were found
to significantly reduce the risk of stroke/SE compared to warfarin (Hazard Ratio (HR): 0.373, 95%
confidence interval (CI): 0.247 - 0.564, p<0.001); but, no significant difference was seen between
NOACs and warfarin in terms of reducing the risk of MI (HR: 0.864, CI: 0.594 – 1.257, p=0.446).
NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008)
and OB (HR: 0.608, CI: 0.424 – 0.870, p=0.007); but no difference was seen in the risk of MGB
(HR: 0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. NOACs were also found
to reduce the risk of all-cause mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007). The composite
of effectiveness and safety outcomes, and all-cause mortality was statistically significant proving
superior overall effectiveness and safety of NOAC therapy to warfarin therapy in terms of risk
reduction (HR:0.685, CI:0.587 – 0.801, p<0.001).
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Conclusion: Oral anticoagulation therapy with NOACs was found to be more effective than
warfarin therapy. Results of this study may assist in clinical decision-making about anticoagulation
therapies used in elderly NVAF patients with DM.
Keywords: warfarin, stroke, novel oral anticoagulants, atrial fibrillation, diabetes
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INTRODUCTION
Atrial fibrillation (AF) is the most common heart rhythm disorder in the United States [1]. The
annual prevalence of AF in the US population was estimated at 5.2 million in 2010 and projected
to increase to 12.1 million by 2030, corresponding to an annual growth rate of 4.3 percent [2].
Advancing age is the most prominent risk factor for AF with a 1-in-4 lifetime risk after age 40
years [3,4]. The Framingham study reported a five-fold increase in the risk of stroke with
advancing age in AF patients [5], while the Scottish Renfrew/Paisley study with a 20-year followup found a three-fold increase in the risk of stroke among AF patients [6]. Diabetes is another
independent risk factor of AF with a prevalence of ranging from 24 – 30 percent among AF patients
[7,8]. The relationship between diabetes mellitus and AF is mutual and reciprocal. Incidence of
AF in patients with diabetes has been reported around 14.9% [9]. An observational study assessing
the impact of diabetes mellitus (DM) on AF reported that over a mean follow-up of 7.2 ± 2.8 years,
diabetic patients without AF at baseline had an age- and sex-adjusted incidence rate of AF 9.1 per
1,000 person-years (95% CI: 8.6–9.7) compared with a rate of 6.6 (95% CI: 6.2–7.1) among
nondiabetic patients [10]. Among diabetes patients, AF was independently associated with a 61
percent greater risk for vascular death and all-cause mortality and higher risks for cardiovascular
death and heart failure when compared with patients without AF [11].
Since 1950s, vitamin K antagonists (VKA) such as warfarin and low molecular weight
heparins (LMWH) were used for anticoagulation treatment in AF patients. A meta-analysis of
thromboembolic and bleeding outcomes by Hart et al. comparing warfarin to antiplatelet drugs in
AF patients found warfarin to reduce the risk of stroke by 60 percent [12]. Bleeding is the most
common side effect of warfarin and occurs in up to 41 percent of patients treated with warfarin.
Additionally, its use can be cumbersome because of its food and drug interactions, dose
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adjustment, and need for constant monitoring through laboratory testing [12,13]. Literature reports
VKA therapy discontinuation rates of nearly 30-60 percent among patients with AF, and patients
who discontinued therapy had significantly poor anticoagulation control in terms of poor
International Normalized Ratio (INR), lesser Time in Therapeutic Range (TTR), and resultant
underanticoagulation [14–16]. Beginning 2010, a new class of oral anticoagulants, non-vitamin
K antagonists oral anticoagulants (NOACs) were introduced in the US market. Between 2010 and
2015, the US Food and Drug Administration (FDA) approved four NOACs – dabigatran, apixaban,
rivaroxaban and edoxaban – indicated for thromboprophylaxis in patients with non-valvular AF
(NVAF). Of these, dabigatran is a direct thrombin inhibitor while others are factor Xa inhibitors.
Direct targeting of factor Xa and thrombin provides a faster onset of action compared to warfarin,
predictable pharmacokinetics and pharmacodynamics with a lesser potential for food and drug
interactions allows for better fixed dosing schedules without dietary restrictions or routine
coagulation monitoring [13].
Several randomized clinical trials (RCTs) have demonstrated that NOACs have at least
equivalent efficacy and safety as compared to warfarin in terms of stroke/systemic embolism (SE)
reduction and major hemorrhage rates, in patients with NVAF [17–20]. Results of phase III RCTs
conducted in a sub-group of NVAF patients with diabetes report that NOACs have superior
efficacy compared to warfarin. However, the safety profile of NOACs present a complex scenario.
Bleeding events of NOACs were found to vary by a specific NOAC and dosage. While high dose
edoxaban (60 mg) [20], as compared to low dose edoxaban (30 mg) and warfarin, reduced major
bleeding in both NVAF patients with and without diabetes, apixaban [21] reduced major bleeding
only among nondiabetic patients with NVAF, with no significant interaction by diabetes status.
Interestingly, in patients with diabetes and NVAF, dabigatran and rivaroxaban were not
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significantly different from warfarin in reducing the risk of major bleeding, and there was no
significant interaction by diabetes status [22,23].
Proven efficacy and safety in RCTs, and the pharmacological characteristics of NOACs
contribute to their practical advantages over traditional VKA therapy in reducing thromboembolic
risk [13]. With widespread adoption of NOACs in the routine practice, several observational
studies have been conducted to assess real world effectiveness and safety of these drugs [24–31].
These studies report a comparable or superior performance of NOACs to warfarin in stroke/SE
reduction in patients with AF, but a variation in bleeding outcomes. Apixaban was found to have
the lowest bleeding risk as compared to warfarin followed by dabigatran and rivaroxaban.
Rivaroxaban was associated with higher bleeding risk as compared to warfarin, especially in
elderly population [32–34].
While research has been conducted in the geriatric population with AF and diabetic patients
with NVAF, no real world evidence is available in comparing the effectiveness and safety of
NOAC therapy with warfarin in elderly NVAF patients with comorbid diabetes [35]. NVAF
patients with DM are at an increased risk of thromboembolic and bleeding events due to the
synergistic effect of DM and aging. Given the complex clinical interactions between AF and
diabetes, care for elderly NVAF patients with DM can be complicated. Evidence obtained through
this observational study may assist in clinical decision-making pertaining to the choice of oral
anticoagulation therapy in patients with simultaneous presence of both AF and DM [35,36]. This
study seeks to assess the comparative effectiveness and safety of NOAC therapy versus traditional
warfarin therapy in elderly NVAF patients with concomitant diabetes mellitus using 5% national
Medicare data.

39

METHODS
Data Source
A retrospective cohort study was conducted using the 2014-2016 5% national Medicare
administrative claims data from the Centers of Medicare and Medicaid Services (CMS). Medicare
is the federal health insurance program for those aged ≥65 years, people with disabilities, and
people with end-stage renal disease in the United States, with an estimated 38 million fee-forservice beneficiaries [37]. Medicare administrative claims include information on hospital
inpatient, outpatient, Medicare carrier, Part D, skilled nursing facility, home health agency, and
durable medical equipment claims. The medical claims are coded using International
Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision
(ICD-10-CM), Current Procedural Terminology, or Healthcare Common Procedure Coding
System codes. Pharmacy claims include information on drugs dispensed using the National Drug
Code coding system.
Study Population
Elderly patients aged ≥65 years with NVAF and diabetes mellitus having at least one pharmacy
claim for a NOAC (dabigatran, rivaroxaban, apixaban or edoxaban) or warfarin between July 1,
2014 to December 31, 2015 were selected. Index date was defined as the date of first new
prescription claim for a NOAC or warfarin between July 1, 2014 to December 31, 2015. To ensure
the inclusion of only treatment-naïve NOAC and warfarin users, a rolling pre-index period of six
months was used to confirm that the patients did not have a prior exposure to NOACs or warfarin.
The time period from index date to December 31, 2016 was used for identification of outcomes;
thus, ensuring that each patient had at least 12 months of follow-up period.
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Patients were required to have continuous medical (Part A and Part B) and pharmacy (Part
D) enrolment for six months prior to the index date. In Medicare data, beneficiary Part A and Part
B enrollment information is available as single variables showing number of months a beneficiary
was enrolled in Medicare Part A and Part B in a given calendar year. Since, a rolling pre-index
period was used, patients having pre-index period spread across 2014 and 2015 were required to
have at least three months of Part A and Part B continuous enrollment in each calendar year.
Patients were required to have one or more inpatient or outpatient claims carrying a diagnosis code
for NVAF (ICD-9-CM code 427.31 and ICD-10-CM code I48.0, I48.1, I48.2, I48.91) [38] and
have at least two outpatient claims or at least one inpatient claim for diabetes (ICD-9-CM code
250.* and ICD-10-CM code E11.*) within the six-month pre-index period [39].
Patients with evidence of valvular heart disease, heart valve replacement or surgery, venous
thromboembolism (VTE), pulmonary embolism, transient AF (pericarditis, hyperthyroidism,
thyrotoxicity), and end-stage renal disease in the pre-index period were excluded from the
study.[30,31] Patients who underwent hip or knee replacement surgery within six weeks prior to
the index date were excluded. This study also excluded beneficiaries with dual eligibility for
Medicare and Medicaid, and those enrolled in health maintenance organizations (HMOs) during
the study period.
Patients were followed from the index date till the oral anticoagulant (OAC) prescription
discontinuation date, switch to another class of OAC drug other than the index drug class, death,
loss of continuous enrollment or end of the study period (December 31, 2016), whichever occurred
first. Fill dates and days supplied per prescription were used to determine patients’ treatment
episodes, defined as the period from the first fill date to the date when there were no residual days
of supply. Patients were considered as continuing on the treatment as long as they had another

41

medication fill of the same drug class within 45 days of the end of the last treatment episode [40–
43].
Outcome Measures
Clinical outcomes associated with NOAC or warfarin therapy were measured from the index date
of NOAC or warfarin therapy till the oral anticoagulant (OAC) prescription discontinuation date,
switch to another class of OAC drug other than the index drug class, death, loss of continuous
enrollment or end of the study period (December 31, 2016), whichever occurred first. Primary
outcomes were classified as effectiveness and safety outcomes. Effectiveness outcomes included
thromboembolic episodes – stroke or systemic embolism (SE), and myocardial infarction (MI).
Safety outcomes included major bleeding episodes - gastrointestinal bleeding (MGB), intracranial
bleeding (ICH), and major bleeding from other sites (OB). Composite effectiveness and composite
safety outcomes comprising of occurrence of any of the effectiveness or safety outcomes,
respectively, were also evaluated. Secondary outcome was a composite of stroke or systemic
embolism (SE), myocardial infarction (MI), gastrointestinal bleeding, intracranial bleeding,
bleeding from other sites, and all-cause mortality. In case a patient encountered multiple clinical
outcomes, the occurrence of the first event was considered for the composite outcome measure.
Outcomes were identified using the Medpar, Outpatient, and Carrier files in the Medicare data.
All-cause mortality (i.e. patients who died regardless of the reason for death) was identified based
on the date of death information from the Medicare beneficiary summary file.
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Covariates
Pre-index period was used for assessment of patient demographics and clinical characteristics
(clinical risk scores, comorbidities, and concomitant medication use). Comorbidities were
evaluated using Charlson comorbidity index and chronic disease count. Chronic disease count was
a simple total of all chronic conditions ever documented for a patient before the index date. This
information was obtained using the Medicare Beneficiary Summary File – Chronic Condition
Summary File. Baseline risk of stroke and major bleeding was assessed using the modified
CHADS2, CHA2DS2-VASc, and HAS-BLED scores. Since the study population consists of NVAF
patients with diabetes, diabetes was excluded as a risk factor in calculating CHADS2 and
CHA2DS2-VASc risk scores. CHA2DS2-VASc stroke risk score was based on CHADS2 and
calculated as the summed total of the points determined for each diagnosis (congestive heart
failure, hypertension, aged >75 years, prior stroke or transient ischemic attack, or
thromboembolism, vascular disease, aged 65-74 years, and sex). Modified HAS-BLED bleeding
risk score was calculated based on evidence of hypertension, abnormal kidney or liver function,
stroke, bleeding, age >65 years, and drugs/alcohol abuse or dependence. Labile International
Normalized Ratio (INR) is a component of HAS-BLED score. However, since this information is
not available in Medicare administrative claims data, modified HAS-BLED score with range 0 to
8 was calculated [31]. Concurrent medication use was assessed based on paper by Kocis et al.
which describes the extent to which patients with NVAF take chronic medications, other than
anticoagulants, more frequently than once daily [44].
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Statistical Analysis
Descriptive statistics were used to summarize the baseline characteristics of the study cohort.
Frequencies and proportions were reported for categorical variables and means with standard
deviations (SD) were reported for continuous variables.
Patients initiating NOAC or warfarin therapy were expected to differ on baseline
demographic and clinical characteristics and comorbidities. Since the treatment was main variable
of interest, propensity score matching was used to create the final analysis cohort. Propensity
scores were calculated for each patient using multivariable logistic regression. Each patient who
initiated NOAC therapy was matched with a patient who initiated warfarin therapy using a greedy
matching algorithm (i.e. the Mayo gmatch macro) [45] based on the calculated propensity scores
and the index date of the therapy. Patients were matched on a 1:1 basis using a caliper width of
0.05 for the propensity score and time period of ±15 days for the index date. Standardized mean
differences were used to assess the balance of the measured covariates and a difference of less than
10% was used to indicate clinically irrelevant difference in the measured variables between the
matched groups [46,47]. Since the propensity score matching algorithm picks out the nearest
available match based on the caliper width, patients who initiated NOAC therapy could still differ
on baseline characteristics from patients who initiated warfarin therapy. These group differences
were calculated using standardized differences in the total and the matched sample (Table 1).
The time to each outcome of interest for the propensity-score-matched NOAC and warfarin
treatment cohort was compared using Kaplan–Meier survival curves and tested for differences
using log-rank tests. Incidence rates of stroke or SE, MI, and major bleeding episodes in the
propensity score-matched cohort were calculated as the number of stroke/SE, MI, and major
bleeding events per 100-person years. Stratified Cox proportional hazards regression were used to
compare outcomes in the propensity score-matched cohort, with STRATA statement in PROC
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PHREG procedure to account for the clustering within matched groups. Proportional hazards
assumption was tested and found valid for all outcomes [48]. All statistical analyses were
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
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RESULTS
Of 5,833 eligible patients with NVAF and diabetes before propensity score matching, 2,509
patients (43.01%) were initiated on warfarin therapy and 3,324 patients (56.99%) initiated on
NOAC therapy between July 1, 2014 and December 31, 2015. Demographic and clinical
characteristics of treatment groups before matching are outlined in Table 1a. Patients initiating
warfarin therapy were more likely to have history of prior bleeding (21.96% vs. 16.94%, p<0.001),
congestive heart failure (65.80% vs. 57.19%, p<0.001), myocardial infarction (10.20% vs. 7.49%,
p<0.001), coronary artery disease (46.99% vs. 43.74%, p=0.014), and renal disease (60.46% vs.
50.06%, p<0.001). However, no significant difference was seen between two treatment groups in
the history of stroke (15.46% vs. 14.89%, p=0.546). Mean follow-up time for patients initiating
NOAC and warfarin therapy was 12.07±8.23 months and 10.11±7.74 months respectively.
After 1:1 propensity score matching, 2291 warfarin-NOAC matched pairs were obtained.
Demographic and clinical characteristics of the matched treatment groups are outlined in Table
1b. Comparison of treatment groups after propensity score matching on baseline demographic and
clinical characteristics did not show significant differences (standardized difference >10%). Figure
1 depicts the distribution of the propensity scores before and after matching. Before matching, the
distribution of the propensity scores was different between the NOAC and warfarin treatment
groups, which indicates that the groups differed significantly in baseline demographics and
comorbidities. The graphs overlap almost perfectly in the matched sample indicating that the two
groups have a similar distribution of propensity scores. All further analyses were carried out on
the propensity-score matched sample.
An evaluation of long-term effectiveness and safety outcomes revealed that a significantly
higher proportion of patients initiating warfarin therapy experienced stroke/SE (4.23% vs. 2.44%,
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p<0.001) and composite outcome (23.13% vs. 20.12%, p=0.013) as compared to patients who
initiated NOAC therapy. Although a greater proportion of patients who initiated warfarin therapy
experienced ICH (2.62% vs. 1.79%, p=0.056), OB (4.41% vs. 3.32%, p=0.055), and death (11.17%
vs. 10.08%, p=0.231), these differences were not statistically significant. No differences were seen
in the proportion of patients experiencing MI (3.58% vs. 3.36%, p=0.686) and MGB (5.33% vs.
5.63%, p=0.649).
Table 1a. Baseline demographic and clinical characteristics of the study before propensity
score matching
Variable

Warfarin users
(N= 2509)

NOAC users
(N= 3324)

Absolute
Standardized
difference

N /Mean % / SD N /Mean % / SD
77.15
7.22
77
7.29

Age, years
Age, years
65 - 74
75 - 84
85 and above

990
1072
447

39.46
42.73
17.82

1382
1342
600

41.58
40.37
18.05

Gender

0.196
0.050

0.045
Female
Male

1131
1378

45.08
54.92

1526
1798

45.91
54.09

Race
White
Non-white
US geographic region
Northeast
North Central
West
South
Baseline clinical
characteristics
Charlson Comorbidity Index
score
Chronic Disease Count Score

0.043
2326
183

92.71
7.29

3086
238

92.84
7.16

620
682
350
857

24.71
27.18
13.95
34.16

720
733
449
1422

21.66
22.05
13.51
42.78

3.07

2.95

2.54

2.79

0.184

9.00

2.91

8.56

2.98

0.149

0.186
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Modified CHA2DS2-VASc
score
CHADS2 score
Modified HAS-BLED score

5.23

1.34

5.10

1.37

0.108

3.57
3.30

1.07
1.01

3.45
3.14

1.10
0.99

0.111
0.157

551
388
55
1651
2481
1517
256
1179
184
503
178

21.96
15.46
2.19
65.80
98.88
60.46
10.20
46.99
7.33
20.05
7.09

563
495
32
1901
3266
1664
249
1454
269
597
187

16.94
14.89
0.96
57.19
98.26
50.06
7.49
43.74
8.09
17.96
5.63

0.127
0.016
0.099
0.178
0.053
0.210
0.096
0.065
0.028
0.053
0.060

Medical history
Prior bleeding
Prior stroke
Prior systemic embolism
Congestive heart failure
Hypertension
Renal disease
Myocardial infarction
Coronary artery disease
Transient ischemic attack
Peripheral vascular disease
Abnormal liver function
Baseline medication use
Angiotensin converting
903
35.99
1212
36.46
enzyme (ACE) inhibitors
Diuretics
1318
52.53
1630
49.04
Statins
1676
66.80
2209
66.46
Beta blockers
1830
72.94
2454
73.83
Calcium channel blockers
893
35.59
1185
35.65
H2 receptor antagonists
177
7.05
204
6.14
Proton pump inhibitors
833
33.20
1059
31.86
Anti-platelet agents
438
17.46
602
18.11
NSAIDs
206
8.21
347
10.44
Anti-arrhythmic agents
908
36.19
1239
37.27
Anti-anginal agents
445
17.74
425
12.79
Antidiabetic agents
1444
57.55
1896
57.04
Opioids
901
35.91
1143
34.39
Antidepressants
630
25.11
834
25.09
Benzodiazepines
235
9.37
312
9.39
Potassium supplements
582
23.20
690
20.76
Thyroid hormonal drugs
543
21.64
789
23.74
Anti-gout drugs
218
8.69
218
6.56
Anti-adrenal agents
461
18.37
591
17.78
NOACs, Non-vitamin K antagonists oral anticoagulants; SD, Standard Deviation
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0.010
0.070
0.007
0.020
0.001
0.037
0.029
0.017
0.077
0.023
0.134
0.010
0.032
0.004
0.006
0.060
0.050
0.080
0.015

Table 1b. Baseline demographic and clinical characteristics of the study after propensity
score matching
Variable

Warfarin users
(N= 2291)

NOAC users
(N= 2291)

N /Mean % / SD N /Mean % / SD
77.15
7.22
77.20
7.25

Age, years
Age, years
65 - 74
75 - 84
85 and above

909
974
408

39.68
42.51
17.81

926
941
424

Absolute
Standardized
difference
0.008
0.016

40.42
41.07
18.51

Gender

0.015
Female
Male

1051
1240

45.88
54.12

1036
1255

45.22
54.78

White
Non-white

2131
160

93.02
6.98

2130
161

92.97
7.03

Race

0.015

US geographic region
Northeast
North Central
West
South
Baseline clinical
characteristics
Charlson Comorbidity Index
score
Chronic Disease Count Score
Modified CHA2DS2-VASc
score
CHADS2 score
Modified HAS-BLED score

0.034
554
601
313
823

24.18
26.23
13.66
35.92

559
568
317
847

24.40
24.79
13.84
36.97

2.98

2.91

2.74

2.86

0.045

8.91
5.23

2.93
1.34

8.86
5.18

2.93
1.37

0.016
0.025

3.55
3.26

1.08
1.01

3.53
3.23

1.09
0.98

0.017
0.035

474
348
36
1456
2263
1331

20.69
15.19
1.57
63.55
98.78
58.10

447
343
26
1450
2262
1302

19.51
14.97
1.13
63.29
98.73
56.83

0.029
0.006
0.038
0.005
0.004
0.025

Medical history
Prior bleeding
Prior stroke
Prior systemic embolism
Congestive heart failure
Hypertension
Renal disease
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Myocardial infarction
Coronary artery disease
Transient ischemic attack
Peripheral vascular disease
Abnormal liver function

221
1066
174
450
155

9.65
46.53
7.59
19.64
6.77

197
1050
163
444
146

8.60
45.83
7.11
19.38
6.37

Baseline medication use
Angiotensin converting
841
36.71
827
36.10
enzyme (ACE) inhibitors
Diuretics
1170
51.07
1182
51.59
Statins
1531
66.83
1540
67.22
Beta blockers
1680
73.33
1673
73.02
Calcium channel blockers
825
36.01
824
35.97
H2 receptor antagonists
157
6.85
159
6.94
Proton pump inhibitors
752
32.82
769
33.57
Anti-platelet agents
413
18.03
396
17.29
NSAIDs
199
8.69
208
9.08
Anti-arrhythmic agents
824
35.97
862
37.63
Anti-anginal agents
375
16.37
343
14.97
Antidiabetic agents
1310
57.18
1306
57.01
Opioids
815
35.57
796
34.74
Antidepressants
562
24.53
599
26.15
Benzodiazepines
219
9.56
224
9.78
Potassium supplements
509
22.22
494
21.56
Thyroid hormonal drugs
495
21.61
550
24.01
Anti-gout drugs
194
8.47
149
6.50
Anti-adrenal agents
414
18.07
413
18.03
NOACs, Non-vitamin K antagonists oral anticoagulants; SD, Standard Deviation

0.036
0.014
0.018
0.007
0.016

0.013
0.010
0.008
0.007
0.001
0.003
0.016
0.019
0.014
0.034
0.038
0.003
0.017
0.037
0.007
0.016
0.057
0.005
0.001

Incidence rates of clinical outcomes are presented in Table 2 and Table 3. As compared to
patients initiating warfarin therapy, patients initiating NOAC therapy were found to have
significantly lower incidence of stroke/SE as compared to warfarin (2.322 per 100 person-years
vs. 4.776 per 100 person-years, p<0.001), ICH (2.909 vs. 1.685, p=0.008), OB (4.966 vs. 3.162,
p=0.003), and all-cause mortality (12.330 vs. 9.451, =0.004). No significant differences were
observed in the incidence rates of MI (4.003 vs. 3.186, p=0.383) and MGB (5.991 vs. 5.385,
p=0.916) between patients initiating NOACs versus patients initiating warfarin.
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Table 2. Hazard ratio of effectiveness outcomes in propensity-score matched cohort
Outcome

Incidence rate per
100 person-years

Hazard ratio (95%
confidence intervals)

p value

Warfarin NOACs
4.776
2.322
4.003
3.186
8.481
5.279

Stroke/SE
0.373 (0.247 - 0.564)
<0.001
Myocardial infarction
0.864 (0.594 - 1.257)
0.446
Composite effectiveness
0.567 (0.428 - 0.757)
<0.001
outcomea
a
A composite of stroke, systemic embolism (SE), and myocardial infarction (MI)
Table 3. Hazard ratio of safety outcomes in propensity-score matched cohort
Outcome
Major Bleeding
Intracranial
Gastrointestinal
Other
Composite safety
outcomea

Incidence rate per
100 person-years
Warfarin NOACs

Hazard ratio (95%
confidence intervals)

p value

2.909
5.991
4.966

1.685
5.385
3.162

0.500 (0.300 – 0.834)
0.862 (0.640 – 1.160)
0.608 (0.424 – 0.870)

0.008
0.326
0.007

12.786

9.669

0.701 (0.563 - 0.873)

0.002

All-cause mortality
12.330
9.451
0.783 (0.656 – 0.935)
0.007
b
Composite outcome
27.444
19.999
0.685 (0.587 - 0.801)
<0.001
a
A composite of ICH, MGB, and OB
b
A composite of stroke, systemic embolism (SE), myocardial infarction (MI), gastrointestinal
bleeding (MGB), intracranial bleeding (ICH), bleeding from other sites (OB), and all-cause
mortality
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Figure 1. Distribution of propensity scores before and after matching for NOAC and
warfarin therapy among Medicare beneficiaries matched on propensity score and date of
surgery
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Figure 2. Kaplan-Meier survival curves for NOAC and warfarin therapy among Medicare
beneficiaries with NVAF and DM
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Hazard ratios for effectiveness outcomes are presented in Table 2. Refer Figure 2 for
Kaplan Meier (KM) plots of effectiveness and safety outcomes. Survival curves for occurrence of
stroke/SE were significantly different for NOAC patients and warfarin patients as evident from
significant log-rank test (p<0.001); however, the survival curves for MI with two therapies seemed
to overlap (p=0.215). NOACs were found to significantly reduce the risk of stroke/SE compared
to warfarin (Hazard Ratio (HR): 0.373, 95% confidence interval (CI): 0.247 - 0.564, p<0.001);
but, no significant difference was seen between NOACs and warfarin in terms of reducing the risk
of myocardial infarction (HR: 0.864, CI: 0.594 – 1.257, p=0.446). Overall, effectiveness of
NOACs was found to be superior compared to warfarin as measured using the composite
effectiveness outcome comprising of occurrence of either stroke/SE or MI. Superiority was seen
in both – risk reduction of stroke/SE or MI (HR: 0.629, CI: 0.457 – 0.866) and longer survival
time for these outcomes (p<0.001).
Hazard ratios for safety outcomes are presented in Table 3. NOACs were found to
significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008) and bleeding from
other sites (HR: 0.608, CI: 0.424 – 0.870, p=0.007) and prolong the occurrence as seen from
significantly different survival curves for ICH (p=0.006) and OB (p=0.008). However, the survival
curves for MGB almost overlapped (p=0.562) and no difference was seen in the risk of MGB (HR:
0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. The composite safety outcome
of major bleeding events (occurrence of any of the three safety outcomes) was significant
(HR:0.701, CI:0.563 – 0.935, p=0.002). NOACs were also found to reduce the risk of all-cause
mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007) and increase overall survival (p<0.001). The
composite of effectiveness and safety outcomes, and all-cause mortality was statistically
significant proving superior overall effectiveness and safety of NOAC therapy to warfarin therapy
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in terms of risk reduction (HR:0.685, CI:0.587 – 0.801, p<0.001) and prolongation of survival
(p<0.001).
DISCUSSION
Given their practical advantages over traditional warfarin therapy, NOACs have become first
choice of oral anticoagulation therapy in patients with NVAF. However, patients with DM
constitute a unique subgroup among NVAF patients, having a significantly higher risk of both
thromboembolic episodes and hemorrhagic events. Given the diabetes-related propensity for both
thromboembolic and hemorrhagic events, the issue of whether NOACs maintain their better
efficacy and safety profile as compared to warfarin in the high-risk setting of diabetic patients is
clinically relevant. Further, care of elderly NVAF patients with concomitant diabetes presents a
highly vulnerable segment of population which demands special consideration with respect to oral
anticoagulation therapy. While several observational studies have been conducted to assess
comparative effectiveness and safety of NOACs versus warfarin in elderly NVAF population, ours
is the first study to evaluate the effectiveness and safety of NOACs compared to warfarin in elderly
NVAF population with DM. In this study, we compared the risk of thromboembolic episodes and
hemorrhagic events in elderly NVAF patients with concomitant DM using the 5% national
Medicare sample from 2014-2016. Propensity score matching was used to control for baseline
patient demographic and clinical characteristics.
Our study found a greater incidence rate of stroke/SE, ICH, OB, and all-cause mortality
among patients on warfarin therapy compared to patients using NOACs. We believe a greater
incidence of clinical outcomes was observed given the baseline demographic composition and
clinical characteristics of our study population which represents a high-risk and vulnerable group
of patients with AF. High risk of stroke in our study population is evident through higher
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CHA2DS2-VASc scores (mean modified CHA2DS2-VASc~5) after adjusting for diabetes status in
both treatment groups. A significant proportion of study population had a history of prior stroke
and prior bleeding. Prior stroke has been known to increase the risk of recurrent ischemic attack
and major hemorrhage which might explain higher incidence of stroke/SE and bleeding events in
our study [49,50]. Additionally, a substantial portion of patients in our study were on several
concomitant medication which might increase the risk of hemorrhage [51]. NVAF patients in our
study had a substantial comorbidity burden as evident from the baseline clinical characteristics.
Overall higher incidence of clinical outcomes and all-cause mortality may also be associated to
general presence multiple comorbidities along with NVAF and diabetes in this population.
Using Cox proportional hazards models, the results of the current study showed that
compared to warfarin, NOACs were found to significantly lower the risk of stroke/SE, intracranial
bleeding, bleeding from other sites, and all-cause mortality in elderly patients with NVAF and DM
treated in routine clinical practice. Differences in the risk reduction associated with NOAC and
warfarin therapies may be influenced by differences in pathophysiology of NVAF and DM and
pharmacological action of two drug classes. Pathophysiology of NVAF with concomitant DM is
different from NVAF alone due to complex interaction in molecular mechanisms between NVAF
and DM [36]. Variability of glycemic control in diabetic patients may affect the pharmacokinetics
and anticoagulant activity of warfarin [52]. Additionally, the anticoagulant activity of warfarin is
expressed through non-specific mechanism of action which affects several proteins outside the
coagulation system, in turn, increasing the risk of cardiovascular and hemorrhagic events [53].
These factors may explain increased risk of hemorrhagic events associated with warfarin in
comparison to NOACs.
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Findings of this study are in agreement with the results of 4 large phase III clinical trials of
NOACs - (apixaban in ARISTOTLE [17], dabigatran in RE‐LY[18], rivaroxaban in ROCKET AF
[19], and edoxaban in ENGAGE AF-TIMI 8 [54]) in which 23 - 40 percent of NVAF patients had
diabetes at the baseline. In two meta‐analyses of these four clinical trials, NOACs, compared with
warfarin, were found to reduce the rate of stroke/SE, ICH, and death. This effect was similar among
AF patients with and without diabetes. Similarly, no difference was seen among NVAF patients
with and without diabetes with respect to bleeding events, although the relative safety of NOACs
was apparent more among patients without diabetes [55,56]. Similar pattern of results was
observed in the meta-analysis by Patti et al. [57] which focused specifically on NVAF patients
with concomitant diabetes from the above mentioned 4 phase III clinical trials. Patti et al. reported
that despite patients with diabetes having higher rates of thromboembolic episodes and mortality
and compared to patients without diabetes, similar efficacy of NOACs was observed in both
patients with or without diabetes. The safety of NOACs however, presented a more complex
scenario where rate of hemorrhagic events was found to depend on specific NOAC and its dose
leading to conclusion that risk reduction in hemorrhagic events was higher in AF patients without
diabetes as compared to AF patients with diabetes. Our study found NOACs to significantly reduce
the risk of ICH and bleeding from other sites in elderly NVAF patients with diabetes. However,
no differences were seen in rates of gastrointestinal bleeding between NOACs and warfarin.
Comparability to results found by Patti et al. may be limited since we did not evaluate drug- or
dose-specific effects of NOACs compared to warfarin. Additionally, our study focused only on
NVAF patients with diabetes and hence, assessing comparative effectiveness and safety of NOACs
over warfarin in patients without diabetes was not undertaken.
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Since findings obtained in clinical trials may not always replicate in routine clinical
practice, understanding real-world effectiveness and safety of NOACs versus warfarin in elderly
NVAF population with diabetes is necessary. We found two observational studies evaluating
effectiveness and safety of these drugs. The ARISTOPHANES Diabetes Subgroup Analysis
study[58] used CMS Medicare data and data from four US commercial databases to evaluate
relative effectiveness and safety of NOACs versus warfarin in NVAF patients with diabetes. The
study reported apixaban and rivaroxaban to be associated with lower rates of stroke/SE, while
apixaban and dabigatran had lower rates of MGB compared to warfarin demonstrating overall
superiority of NOACs over warfarin. Coleman et al. assessed effectiveness and safety of
rivaroxaban compared to warfarin in NVAF patients with diabetes using administrative claims
data and found nonsignificant risk reductions in stroke/SE and major bleeding; thus, providing
evidence of rivaroxaban’s non-inferior effectiveness and safety profile in this population [59].
Results of our study agree with the findings of these studies. Comparison of NOACs, as a drug
class, to warfarin in this study provides evidence of better overall effectiveness and safety on
NOACs compared to warfarin.
The synergistic effect of aging and diabetes predisposes patients with NVAF to
thromboembolic and hemorrhagic episodes. Diabetes is associated with numerous metabolic
defects including insulin resistance, impaired glucose tolerance, proinflammatory mediators,
abnormalities of hemostasis, fibrinolysis, and angiogenesis which could lead to precipitation of
adverse cardiovascular events [60,61]. With the advent of NOACs with better pharmacological
profile, warfarin is losing its status as the preferred therapy for thromboprophylaxis, especially in
NVAF patients with DM [52,53]. As NOACs become a preferred therapy for oral
thromboprophylaxis in NVAF patients [62], there is a need for more real-world evidence
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supporting the effectiveness and safety profile of NOACs compared to warfarin in the high-risk
group of elderly AF patients with concomitant diabetes.
The current study has several strengths. First, this study used real world data on patients
receiving care in actual clinical practice. The study results are therefore more generalizable
compared to results of previous randomized clinical trials. Second, patients initiating NOAC or
warfarin therapy were matched on baseline demographics and comorbidities using propensity
scores. In addition, patients were also matched on the index date of the NOAC and warfarin
prescription. The matching process reduces the likelihood of selection bias in observational studies
ensuring that all baseline characteristics are balanced equally across treatment groups. Thirdly,
effectiveness and safety of NOACs versus warfarin was assessed in a high-risk group of elderly
patients over a broad set of clinical outcomes which better characterized the superiority of NOACs,
as a drug class, over warfarin.
Results of this study should be interpreted in the light of some limitations. Owing to sample
size limitations, we evaluated effectiveness and safety of NOACs as a drug class instead of
comparing individual NOAC to warfarin. It is possible that effectiveness or safety outcomes of
individual NOACs may not exhibit similar results. Although, the treatment groups were matched
using propensity scores, potential residual confounders still exist; e.g. over-the counter aspirin use
and warfarin dose adjustment, which are not available in the dataset. Claims data lack laboratory
data and accuracy in coding diagnoses. AF and DM were identified using ICD-9-CM and ICD-10CM codes, which is different from clinical trials. Additionally, the presence of a claim for a filled
prescription does not indicate whether the medication was consumed or taken as prescribed.
Compared with clinical trials, the follow-up period for the cohort in this study was also shorter,
which may impact our results. Finally, although understanding the US Medicare population is
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important in managing NVAF, findings from this elderly population may not be generalized to
other populations.

61

CHAPTER IV
CONCLUSION
NOACs and warfarin are common drugs of choice for thromboprophylaxis in patients with AF.
The current study compared relative effectiveness and safety of NOACs versus warfarin in a broad
set of clinical outcomes in real world patients after accounting for baseline differences between
the two patient groups. Our study found that NOACs, as a class, reduced the risk of stroke/SE,
intracranial bleeding, bleeding from other sites, and all-cause mortality in elderly NVAF patients
with diabetes. No significant differences were seen in the risk of myocardial infarction and major
gastrointestinal bleeding. Overall, NOACs appeared to be the superior oral anticoagulation
strategy for elderly NVAF patients with diabetes. Evidence from this study can assist clinical
decision-making about choice of thromboprophylaxis therapy in elderly NVAF patients with
diabetes. However, individual patient factors should be taken into consideration in addition to
clinical evidence while making clinical decisions about anticoagulation therapy.
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APPENDIX A: SUPPLEMENTAL TABLES
Supplemental table 1. ICD-9-CM and ICD-10-CM codes for exclusion criteria
ICD-9-CM Diagnosis or
Procedural Codes
Rheumatic mitral valvular 394.0, 394.1, 394.2, 394.9,
heart disease, mitral valve 396.0, 396.1, 396.8, 396.9,
stenosis
424.0, 745.xx
Heart valve replacement or V422, V433, 35.05-35.09,
surgery
35.20-35.28, 35.97
Venous thromboembolism
451-453, 671.3, 671.4, 671.9,
415.1, 673.2, 673.8
Diagnosis

Transient AF (Heart valve Pericarditis: 006.8, 017.9,
replacement / transplant, 036.41, 074.21, 093.81, 098.83,
pericarditis, thyrotoxicity)
115.93, 390, 391, 392.0, 393,
411.0, 420.90, 420.91, 420.99,
423.0, 423.1, 423.2, 423.8,
423.9
Thyrotoxicity: 242.0, 242.1,
242.2, 242.3, 242.4, 242.8,
242.9
Knee replacement surgery
V43.65
CPT codes: 27445, 27446,
27447, 27486, 27487
Hip replacement surgery
V43.64
CPT codes: 27120, 27122,
27125, 27130, 27132, 27134,
27137, 27138

ICD-10-CM Diagnosis or
Procedural Codes
I05.0-I05.9,
I06.0-I06.9,
I34.0-I34.9, I35.0-I35.9
Z95.2, Z95.3, Z95.4
I80.0-I80.3, I80.8, I80.9,
I82.0-I82.9, I82.A, I82.B,
I82.C
I30.0, I30.1, I30.8, I30.9,
I31.0, I31.1, I31.2, I31.3,
I31.4, I31.8, I31.9, I32
Thyrotoxicity: E05.0-E05.9

Z96.65
CPT codes: 27445, 27446,
27447, 27486, 27487
Z96.64
CPT codes: 27120, 27122,
27125, 27130, 27132, 27134,
27137, 27138

Supplemental Table 2. ICD-9-CM and ICD-10-CM diagnosis codeads for clinical outcomes
Diagnosis

ICD-9-CM codes

Stroke or Systemic Embolism
430.xx - 432.xx, 433.x1,
Stroke
434.x1, 436
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ICD-10-CM codes

I60.0-I60.9, I61.0-I61.9,
I62.0-I62.9, I63.0-I63.9, I64.9

Systemic embolism
444.x, 445.x
Transient ischemic attack
435.x
Major Bleeding
Major intracranial
430, 431, 432.x, 852.x, 853.x
hemorrhage (ICH)
456.0, 456.20, 530.21, 530.7,
530.82, 531.0x, 531.2x,
531.4x, 531.6x, 532.0x,
532.2x, 532.4x, 532.6x,
533.0x, 533.2x, 533.4x,
533.6x, 534.0x, 534.2x,
Major gastrointestinal
534.4x, 534.6x, 535.01,
bleeding (MGB)
535.11, 535.21, 535.31,
535.41, 535.51, 535.61,
535.71, 537.83,
537.84, 562.02, 562.03,
562.12, 562.13, 568.81, 569.3,
569.85, 578.x
Procedure code: 44.43
285.1, 360.43, 362.43, 362.81,
363.61, 363.62, 363.72,
364.41, 372.72, 374.81,
376.32, 377.42, 379.23,
Major bleeding from other
423.0x, 596.7x, 599.7x,
sites
602.1x, 620.1, 621.4, 626.2,
(OB)
626.5, 626.7, 626.8, 626.9,
719.1x, 782.7, 784.7, 784.8,
786.3x, 958.2, 997.02, 998.11
Procedure code: 99.04
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I74.0-I74.9
G45.0-G45.9*
I60, I61, I62.0, I62.1, I62.9

K92.0, K92.1, I85.0, I98.20,
I98.3, K22.10, K22.12,
K22.14, K22.16, K25.0,
K25.2, K25.4, K25.6, K26.0,
K26.2, K26.4, K26.6, K27.0,
K27.2, K27.4, K27.6, K28.0,
K28.2, K28.4, K28.6, K29.0,
K63.80, K31.80, K55.20,
K62.5, K92.2

N02.0, N02.1, N02.2,
N02.3, N02.4, N02.5, N02.6,
N02.7, N02.8, N02.9, K66.1,
N93.8, N93.9, N95.0, R04.1,
R04.2, R04.8, R04.9, R31.0,
R31.1, R31.8, R58, D68.3,
H35.6, H43.1, H45.0, M25.0

Supplemental Table 3. ICD-9-CM and ICD-10-CM codes for comorbidities
Disorder/Disease
Congenital heart disease
Congestive heart failure

ICD-9-CM codes
746.9
428.0

Hypertension

401.9

Peripheral vascular disease

443.9

Hemiplegia
Dementia
Leukemia
Lymphoma
Alcohol use
Tobacco use

342.0
294.20
208.0
202.8*
303.9*
305.1
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ICD-10 codes
Q20-Q28
I50.0-I50.9, I11.0, I13.0,
I13.2
I10.0-I10.9, I11.0-I11.9,
I12.0-I12.9, I13.0-I13.9,
I15.0–I15.9
I21.0-I21.9, I23.0-I23.9,
I70.0, I70.2-I70.9, I71.0I71.9, I73.9
G81
G31.0
C91-C96
C81-C88
F10.1, F10.2, F10.9
F17.2
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Fibrillation and Diabetes’ (Abstract submitted for ISPOR 2019, New Orleans, LA)
▪ Patients initiating NOACs were matched 1:1 to warfarin patients on propensity score to
balance demographic and clinical characteristics.
▪ Primary effectiveness was measured as the risk of stroke/systemic embolism (SE) or
myocardial infarction (MI). Primary safety measures included major bleeding -
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intracranial hemorrhage (ICH), gastrointestinal bleeding (MGB), and bleeding from other
sites (OB).
▪ Cox proportional hazards models were used to estimate the effectiveness and safety
outcomes of NOACs vs warfarin in the matched cohort.
Posters
• Korgaonkar S, Banahan B, Pittman E, Noble S. Effect of Depression on Medication Adherence
to Asthma Controller Medications and Healthcare Resource Utilization in Severe Asthma
Patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23 rd
Annual International Meeting. Baltimore, Maryland. May 19-23, 2018.
• Korgaonkar S, Inguva S, Yang Y. Cost-Effectiveness of Mepolizumab Versus Omalizumab As
an Adjunct Therapy in Patients with Uncontrolled Allergic Asthma. International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting.
Baltimore, Maryland. May 19-23, 2018.
• Dunn T, Korgaonkar S, Ramachandran S. Association Between Stimulant Use and Misuse of
Other Prescription Medications. International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) 23rd Annual International Meeting. Baltimore, Maryland. May 19-23, 2018.
• Korgaonkar S, Ward L, Pohl L, Nicks A. Exploring First Year Professional Pharmacy Students’
Perceptions and Knowledge of Older Adults. American Association of Colleges of Pharmacy
Annual eeting, Boston, MA. July 21–25, 2018.
Projects
• Impact of Diverse Inclusion Criteria on Assessment of HEDIS Asthma Medication Ratio
(AMR) Quality Measure in Mississippi Medicaid (Abstract submitted for ISPOR 2019, New
Orleans, LA)
▪ Sensitivity analyses using varied inclusion criteria was conducted to explore differential
effect on AMR
▪ Potential misclassification of acute asthma cases as persistent asthma cases was identified
• Impact of Occupational Psychosocial Risk Factors on Frequent, Severe Low Back Pain in
the US Working Population (Abstract submitted for ISPOR 2019, New Orleans, LA)
▪ Multivariable logistic regression was used to measure the association between diverse
work-related psychosocial risk factors and frequent, severe low back pain using 2015 NHIS
database
• Assessment first year professional pharmacy students’ perceptions of older adults
▪ Designed a questionnaire based on Geriatric Attitudes Scale and Facts on Aging Quiz using
Qualtrics platform to assess students’ perceptions pre- and post-interview with an older
adult
▪ Assessed the change in students’ perceptions pre- and post-interview with an older adult
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• Long-acting reversible contraceptives (LARCs) and Depo-Provera utilization in
Mississippi Medicaid population
▪ Profiling of Mississippi Medicaid beneficiaries based on LARC and Depo-Provera
utilization according to Code of Eligibility type
• Pediatric use of multiple antipsychotics in Mississippi Medicaid population
▪ Measured monthly use of multiple antipsychotics among children in Mississippi Medicaid
population
PROFESSIONAL AFFILIATIONS AND RESPONSIBILITIES
• Secretary, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) University of Mississippi student chapter (2017-2018)
• Secretary, Rho Chi Honor Society- University of Mississippi Chapter, (2018-present)
• Initiated into Phi Kappa Phi (2018)
AWARDS
• William E. Farlow Fellowship 2018-2019, Department of Pharmacy Administration, University
of Mississippi, August 2018.
• Member of runner-up team, Pharmacy Quality Alliance (PQA) - Healthcare Quality Innovation
Challenge, Baltimore, Maryland. May 2018.
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